On September 8, CANSINOBIO rose 5.47% in regular trading, trading at 30.02 HKD/share, with turnover of approximately HKD 143 million. The rally was driven by a combination of robust interim results and continued momentum in the mRNA oncology vaccine space.

The company's H1 report showed revenue of RMB 5.50 billion, up 43.81% year-over-year, while net loss attributable to shareholders narrowed 94.65% to just RMB 720,800. Notably, overseas revenue surged 4,724.19% to RMB 1.52 billion, reflecting the accelerated monetization of its internationalization strategy through a composite model spanning finished vaccine sales, intermediate product supply, technology transfer, and overseas joint clinical development.

On the pipeline front, CANSINOBIO recently signed a strategic cooperation framework agreement with deepGeneAI to co-develop personalized mRNA therapeutic cancer vaccines targeting gastrointestinal solid tumors and rare cancers. CLSA noted that the company's development route and antigen design are broadly comparable to Moderna's, whose Phase III INTerpath-001 trial for mRNA cancer vaccine intismeran recently achieved its primary endpoint, representing a platform-level valuation re-rating catalyst for peers with similar technology.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)